These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9159603)

  • 21. Cholesterol: precursor to many lipid disorders.
    Jones PH
    Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the management of dyslipidemia.
    Irons BK; Snella KA; McCall K; MacLaughlin EJ; Villarreal M
    Am J Health Syst Pharm; 2002 Sep; 59(17):1615-25. PubMed ID: 12224342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study.
    Eur Heart J; 1997 Nov; 18(11):1718-24. PubMed ID: 9402445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The essence of effective treatment and compliance is simplicity.
    Erhardt LR
    Am J Hypertens; 1999 Oct; 12(10 Pt 2):105S-110S. PubMed ID: 10555610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data.
    Bell KJ; Kirby A; Hayen A; Irwig L; Glasziou P
    BMJ; 2011 Jan; 342():d12. PubMed ID: 21257657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The one-stop coronary cholesterol clinic: a multidisciplinary approach to implementing evidence-based treatment.
    Giles PD; Ramachandran S; Whitaker AJ; Phillips AW; Fell SJ; Mitchell A; Coleman TD
    Postgrad Med J; 1996 Dec; 72(854):744-8. PubMed ID: 9015468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Even at LDL cholesterol 100mg/dl. "Every coronary disease patient has to receive a statin"].
    MMW Fortschr Med; 2003 Dec; 145(49):57. PubMed ID: 14963997
    [No Abstract]   [Full Text] [Related]  

  • 28. Cholesterol and coronary heart disease: screening and treatment.
    Turner-Boutle M
    Nurs Times; 1998 Apr 15-21; 94(15):46-7. PubMed ID: 9615661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of postal prompts to patients and general practitioners on the quality of primary care after a coronary event (POST): randomised controlled trial.
    Feder G; Griffiths C; Eldridge S; Spence M
    BMJ; 1999 Jun; 318(7197):1522-6. PubMed ID: 10356008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coaching patients with coronary heart disease to achieve the target cholesterol: a method to bridge the gap between evidence-based medicine and the "real world"--randomized controlled trial.
    Vale MJ; Jelinek MV; Best JD; Santamaria JD
    J Clin Epidemiol; 2002 Mar; 55(3):245-52. PubMed ID: 11864795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction.
    Grundy SM; Balady GJ; Criqui MH; Fletcher G; Greenland P; Hiratzka LF; Houston-Miller N; Kris-Etherton P; Krumholz HM; LaRosa J; Ockene IS; Pearson TA; Reed J; Smith SC; Washington R
    Circulation; 1997 Mar; 95(6):1683-5. PubMed ID: 9118557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholesterol lowering, sudden cardiac death and mortality.
    de Lorgeril M; Salen P
    Scand Cardiovasc J; 2008 Aug; 42(4):264-7. PubMed ID: 18615354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of lipid lowering in coronary artery disease.
    Goldberg AC
    Curr Opin Cardiol; 1997 Sep; 12(5):488-93. PubMed ID: 9352177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease.
    Eidelman RS; Lamas GA; Hennekens CH
    Arch Intern Med; 2002 Oct; 162(18):2033-6. PubMed ID: 12374510
    [No Abstract]   [Full Text] [Related]  

  • 35. Statins in the medical management of postoperative coronary artery bypass.
    Alexander JC
    Chest; 2005 Feb; 127(2):423-4. PubMed ID: 15705974
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical context: current concepts of coronary heart disease management.
    Jacobson TA
    Am J Med; 2001 Apr; 110 Suppl 6A():3S-11S. PubMed ID: 11311191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delivering effective lipid management in the managed care setting: an interview with Leslee J. Shaw, PhD.
    Shaw LJ
    Am J Manag Care; 2002 Sep; 8(12 Suppl):S323-6. PubMed ID: 12240704
    [No Abstract]   [Full Text] [Related]  

  • 38. Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels.
    Sacks FM; Rouleau JL; Moye LA; Pfeffer MA; Warnica JW; Arnold JM; Nash DT; Brown LE; Sestier F; Rutherford J
    Am J Cardiol; 1995 Mar; 75(8):621-3. PubMed ID: 7887392
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
    Hunninghake DB
    Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of coronary heart disease in primary medical care in Poland: results from the LIPIDOGRAM study.
    Tomasik T; Jozwiak J; Windak A; Rygiel K; Mastej M; Smithson WH; Mathers N; Tomaszewski M; Kaess BM; Tykarski A; Konduracka E; Grzeszczak W; Lukas W
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):287-96. PubMed ID: 21450675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.